|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2011-4-7
|
|
pubmed:abstractText |
Bone-destructive disease treatments include bisphosphonates and antibodies against receptor activator for nuclear factor ?B ligand (aRANKL). Osteonecrosis of the jaw (ONJ) is a side-effect. Aetiopathology models failed to explain their restriction to the jaw. The osteoproliferative transcription factor Msx-1 is expressed constitutively only in mature jaw bone. Msx-1 expression might be impaired in bisphosphonate-related ONJ. This study compared the expression of Msx-1, Bone Morphogenetic Protein (BMP)-2 and RANKL, in ONJ-affected and healthy jaw bone.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
D
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Alkaline Phosphatase,
http://linkedlifedata.com/resource/pubmed/chemical/BMP2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/BMP4 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Bone Density Conservation Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Bone Morphogenetic Protein 2,
http://linkedlifedata.com/resource/pubmed/chemical/Bone Morphogenetic Protein 4,
http://linkedlifedata.com/resource/pubmed/chemical/Diphosphonates,
http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/MSX1 Transcription Factor,
http://linkedlifedata.com/resource/pubmed/chemical/MSX1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/RANK Ligand,
http://linkedlifedata.com/resource/pubmed/chemical/TNFSF11 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/pamidronate,
http://linkedlifedata.com/resource/pubmed/chemical/zoledronic acid
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1601-0825
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
© 2011 John Wiley & Sons A/S.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
433-42
|
|
pubmed:meshHeading |
pubmed-meshheading:21366807-Alkaline Phosphatase,
pubmed-meshheading:21366807-Bone Density Conservation Agents,
pubmed-meshheading:21366807-Bone Morphogenetic Protein 2,
pubmed-meshheading:21366807-Bone Morphogenetic Protein 4,
pubmed-meshheading:21366807-Bone Remodeling,
pubmed-meshheading:21366807-Cell Count,
pubmed-meshheading:21366807-Diphosphonates,
pubmed-meshheading:21366807-Fibroblasts,
pubmed-meshheading:21366807-Humans,
pubmed-meshheading:21366807-Imidazoles,
pubmed-meshheading:21366807-Immunohistochemistry,
pubmed-meshheading:21366807-Jaw Diseases,
pubmed-meshheading:21366807-MSX1 Transcription Factor,
pubmed-meshheading:21366807-Osteoblasts,
pubmed-meshheading:21366807-Osteocytes,
pubmed-meshheading:21366807-Osteonecrosis,
pubmed-meshheading:21366807-Osteopetrosis,
pubmed-meshheading:21366807-RANK Ligand,
pubmed-meshheading:21366807-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:21366807-Signal Transduction
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment.
|
|
pubmed:affiliation |
Department of Oral and Maxillofacial Surgery, University of Erlangen-Nuremberg, Erlangen, Germany. falk.wehrhan@uk-erlangen.de
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
